Smith Group Asset Management’s Regenxbio RGNX Stock Holding History

Smith Group Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-40	Closed	-$2K	–	391
2021 Q2	$2K	Hold	40	–	–	﹤0.01%	360
2021 Q1	$1K	Sell	40 -1,100	-96%	-$46.9K	﹤0.01%	326
2020 Q4	$52K	Hold	1,140	–	–	﹤0.01%	217
2020 Q3	$31K	Hold	1,140	–	–	﹤0.01%	224
2020 Q2	$42K	Sell	1,140 -20	-2%	-$746	﹤0.01%	209
2020 Q1	$38K	Hold	1,160	–	–	﹤0.01%	256
2019 Q4	$48K	Hold	1,160	–	–	﹤0.01%	281
2019 Q3	$41K	Buy	1,160 +420	+57%	+$17K	﹤0.01%	292
2019 Q2	$38K	Hold	740	–	–	﹤0.01%	291
2019 Q1	$42K	Sell	740 -2,800	-79%	-$139K	﹤0.01%	310
2018 Q4	$149K	Sell	3,540 -100	-3%	-$5.87K	0.01%	264
2018 Q3	$275K	Buy	+3,640	New	+$262K	0.01%	232

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Smith Group Asset Management's RGNX Position: Q3 2021 in Review

Smith Group Asset Management sold out of Regenxbio (RGNX) in Q3 2021, closing a stake of 40 shares — an estimated $2K sold.

Smith Group Asset Management first reported a position in RGNX in Q3 2018 and held it in 12 quarters. The position peaked at $275K in Q3 2018. 182 funds tracked by Wall St. Rank hold RGNX as of Q3 2021.

Smith Group Asset Management reported no remaining Regenxbio position as of Q3 2021 after selling out during the quarter.
Smith Group Asset Management sold 40 Regenxbio shares in Q3 2021, an estimated $2K.
Smith Group Asset Management first reported a position in Regenxbio in Q3 2018 and held it in 12 quarters.
Smith Group Asset Management's Regenxbio position peaked at $275K in Q3 2018.
182 funds tracked by Wall St. Rank held Regenxbio as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.